TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Status:
Recruiting
Trial end date:
2030-05-01
Target enrollment:
Participant gender:
Summary
Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has
the same curative effects and less adverse effects than bleomycin, etoposide and
cisplatin(BEP) among newly diagnosed malignant ovarian germ cell tumor patients after
surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Beihua Kong
Collaborators:
Huazhong University of Science and Technology Sun Yat-sen University Zhejiang University